Alto Neuroscience (ANRO) Capital Expenditures (2023 - 2026)

Alto Neuroscience has disclosed Capital Expenditures across 4 years of filings, most recently posting $941000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $941000.0, up 3820.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $941000.0 (down 49.81% YoY), and the FY2025 annual result was $24000.0, down 98.84% from the prior year.
• Capital Expenditures came in at $941000.0 for Q1 2026 at Alto Neuroscience, up from $24000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.0 million in Q3 2024 to a low of -$75000.0 in Q3 2023.
• The 4-year median for Capital Expenditures is $282000.0 (2024), against an average of $351000.0.
• Across the five-year window, Capital Expenditures tumbled 89.29% in 2025 and soared 3820.83% in 2026, its largest moves.
• Alto Neuroscience's Capital Expenditures stood at $470000.0 in 2023, then increased by 7.66% to $506000.0 in 2024, then tumbled by 95.26% to $24000.0 in 2025, then jumped by 3820.83% to $941000.0 in 2026.
• The last three Capital Expenditures figures came in at $941000.0 (Q1 2026), $24000.0 (Q1 2025), and $506000.0 (Q4 2024), per Business Quant data.